Table 2 Patient characteristics
From: Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
Patients enrolled | 18 |
|---|---|
Sex | |
Male | 10 |
Female | 8 |
Age, years | |
Median | 62 |
Range | 46–77 |
ECOG status | |
0 | 4 |
1 | 12 |
2 | 2 |
Cancer Type | |
Adrenocortical | 1 |
Colon | 2 |
Esophageal | 1 |
Fallopian Tube | 1 |
Hepatocellular | 1 |
Leiomyosarcoma | 1 |
Non-Small Cell Lung Carcinoma | 1 |
Ovarian | 1 |
Pancreatic | 3 |
Renal Cell | 2 |
Squamous Cell | 2 |
Transitional Cell | 1 |
Unknown Primary | 1 |
Previous lines of chemotherapy | |
0–3 | 11 |
4–6 | 5 |
>6 | 2 |